Pentamidine

Intravenous pentamidine concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Concomitant intravenous administration of cidofovir and pentamidine is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.

Nephrotoxic agent that may enhance potential for drug-induced renal toxicity. Use concomitantly only with great caution and intensive monitoring of renal function.

Concomitant use may cause severe hypocalcemia and renal impairment; one patient death reported with severe hypocalcemia.

Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits outweigh risks.

May cause hypoglycemia sometimes followed by hyperglycemia. Dose adjustment and glucose monitoring may be required.

Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits outweigh risks.

Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential for higher toxicity from myelosuppression or nephrotoxicity.

Pentamidine impairs gastrointestinal folate uptake through mechanisms affecting folate absorption.

Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.

May cause hypoglycemia sometimes followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be required.

May cause hypoglycemia which may sometimes be followed by hyperglycemia. Dosage adjustment and increased glucose monitoring may be required.

May cause hypoglycemia followed sometimes by hyperglycemia; dosage adjustment and increased glucose monitoring may be required.

May cause hypoglycemia followed sometimes by hyperglycemia. Dosage adjustment and increased glucose monitoring may be required.

May cause hypoglycemia followed by hyperglycemia; dosage adjustment and increased glucose monitoring may be required.

May cause hypoglycemia which may sometimes be followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be required.

May cause hypoglycemia sometimes followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be required.

May cause hypoglycemia followed by hyperglycemia. Dosage adjustment and increased glucose monitoring may be required.

May cause hypoglycemia which may sometimes be followed by hyperglycemia. Dose adjustment and increased glucose monitoring required.

May cause hypoglycemia followed sometimes by hyperglycemia; dose adjustment and glucose monitoring may be required.

May cause hypoglycemia followed sometimes by hyperglycemia. Dose adjustment and increased glucose monitoring required.

May cause hypoglycemia followed sometimes by hyperglycemia; dose adjustment and increased glucose monitoring required.

May cause hypoglycemia sometimes followed by hyperglycemia. Dose adjustment and increased glucose monitoring may be required.

Reduced folate levels have been seen with prolonged intravenous pentamidine.

QT interval prolonging drug. Coadministration with VANFLYTA may further increase incidence of QT prolongation. More frequent ECG monitoring recommended.

Suspected of causing SIADH; may increase pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended.

May cause SIADH, increasing pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended; adjust vasopressin dose as needed.